U.S. Markets close in 5 hrs 47 mins

Rocket Pharmaceuticals, Inc. (RCKT)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
26.14+0.88 (+3.48%)
As of 10:13AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close25.26
Open25.83
Bid26.06 x 900
Ask26.22 x 1000
Day's Range25.77 - 26.38
52 Week Range9.01 - 27.59
Volume44,114
Avg. Volume437,571
Market Cap1.442B
Beta (5Y Monthly)1.65
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Business Wire

    Rocket Pharmaceuticals Reports Second Quarter 2020 Financial Results and Highlights Recent Progress

    Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) ("Rocket"), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today reports financial results for the quarter that ended June 30, 2020, along with an update on the Company's key pipeline developments, business operations and upcoming milestones.

  • Business Wire

    Rocket Pharmaceuticals Announces First Patient Treated in Phase 1 Trial of RP-L301 Gene Therapy for Pyruvate Kinase Deficiency

    Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) ("Rocket"), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces that the first patient has received investigational therapy in the open-label, Phase 1 clinical trial of RP-L301, the Company’s lentiviral vector (LVV)-based gene therapy for the treatment of Pyruvate Kinase Deficiency (PKD), a rare monogenic red blood cell disorder.

  • Business Wire

    Rocket Pharmaceuticals Announces FDA Clearance of IND for RP-L401 Gene Therapy for Infantile Malignant Osteopetrosis

    Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) ("Rocket"), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces that it has received clearance from the U.S. Food and Drug Administration (FDA) for the Company’s Investigational New Drug (IND) application for RP-L401. RP-L401 is the Company’s lentiviral vector (LVV)-based gene therapy for the treatment of Infantile Malignant Osteopetrosis (IMO), a rare, severe monogenic bone resorption disorder characterized by skeletal deformities, neurologic abnormalities and bone marrow failure. RP-L401 was in-licensed from Lund University, under the research leadership of Dr. Johan Richter, M.D., Ph.D. and Dr. Ilana Moscatelli, Ph.D. The vector was in-licensed through a collaboration with Dr. Axel Schambach, M.D., Ph.D. of the Medizinische Hochschule Hannover.